WuXi PharmaTech

Latest Headlines

Latest Headlines

WuXi lands a lead role in Genomics England's big project

Chinese CRO WuXi PharmaTech is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons.

WuXi and Lilly pair up to develop a cardio drug in China

Eli Lilly is partnering with CRO WuXi PharmaTech to develop a cholesterol-lowering pill in China, relying on local expertise in hopes of tapping a growing market.

WuXi and Eli Lilly in pact on cardio candidate development in China

China's WuXi PharmaTech and U.S.-based Eli Lilly plan to develop a candidate to lower cardiovascular risk in patients with dyslipidemia in China that will see the local firm carry the load on development regulatory approval and manufacturing, while the Indianapolis headquarter multinational focuses on sales and marketing.

WuXi pads its revenue on the way to a big buyout decision

Chinese CRO WuXi PharmaTech extended its run of quarterly growth on the eve of a shareholder vote that could take the company private in a multibillion-dollar deal.

Shanghai's WuXi launching clinical device testing services in China

Contract research organization WuXi PharmaTech announced that it's launching preclinical medical device testing services for product registration in China, which is obtained via the China Food and Drug Administration.

WuXi takes its genomics biz to Qatar with new hospital partnership

WuXi PharmaTech, working to expand the adoption of its new clinical genomics service, partnered up with a large Qatari hospital to sequence the genomes of patients and help guide treatment.

WuXi brings its genomic heft to Chinese patients with hospital pact

WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.

WuXi looks to Japan for manufacturing growth

WuXi PharmaTech's small-molecule business won approval to produce drugs in Japan, extending the CRO's reach as it looks to beef up its manufacturing revenue.

China's iKang seeks to delist from U.S. in latest healthcare exit

China's iKang Healthcare wants to go private in a management-led $1.1 billion offer that would see it delist from the U.S., making it among a handful of healthcare-related companies from the Middle Kingdom to pursue that strategy this year.

WuXi inks lab testing pact with Chinese Lee's Pharm

Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.